DE4307262A1 - Magnetic polymeric silicon dioxide - Google Patents

Magnetic polymeric silicon dioxide

Info

Publication number
DE4307262A1
DE4307262A1 DE4307262A DE4307262A DE4307262A1 DE 4307262 A1 DE4307262 A1 DE 4307262A1 DE 4307262 A DE4307262 A DE 4307262A DE 4307262 A DE4307262 A DE 4307262A DE 4307262 A1 DE4307262 A1 DE 4307262A1
Authority
DE
Germany
Prior art keywords
magnetic
silicon dioxide
silica
compounds
dioxide compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE4307262A
Other languages
German (de)
Inventor
Christian Bergemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE4307262A priority Critical patent/DE4307262A1/en
Publication of DE4307262A1 publication Critical patent/DE4307262A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/189—Host-guest complexes, e.g. cyclodextrins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
    • B01D53/02—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols by adsorption, e.g. preparative gas chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
    • B01D53/26—Drying gases or vapours
    • B01D53/28—Selection of materials for use as drying agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
    • B01J20/103—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate comprising silica
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
    • B01J20/28009—Magnetic properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/28026—Particles within, immobilised, dispersed, entrapped in or on a matrix, e.g. a resin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28057—Surface area, e.g. B.E.T specific surface area
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/74—Iron group metals
    • B01J23/745—Iron
    • B01J35/33—
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B03—SEPARATION OF SOLID MATERIALS USING LIQUIDS OR USING PNEUMATIC TABLES OR JIGS; MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C—MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS
    • B03C1/00—Magnetic separation
    • B03C1/005—Pretreatment specially adapted for magnetic separation
    • B03C1/01—Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
    • H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
    • H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
    • H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
    • H01F1/0063—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use in a non-magnetic matrix, e.g. granular solids

Abstract

Process for the preparation of magnetic polymeric silicon dioxide compounds in the form of silica gel, silica sol, precipitated or pyrogenic silicon dioxide, by incorporation of magnetic materials into their matrix. The many possible applications in the sectors of process technology, chemical technology, analysis, biotechnology and pharmacy result from the possibility of influencing such compounds magnetically.

Description

Polymeres Siliciumdioxid in Form von Kieselgelen, Kieselsolen und gefällten oder pyrogenen Silicium­ dioxid findet zahlreiche Anwendungsgebiete in der Verfahrenstechnik, der chemischen Technologie und Pharmazie.Polymeric silica in the form of silica gels, Silica sols and precipitated or pyrogenic silicon Dioxide finds numerous areas of application in process engineering, chemical technology and pharmacy.

Bedingt durch die hohe Absorptionsfähigkeit, die große Oberfläche und chemische Stabilität wird Siliciumdioxid als Katalysatorträger, zum Reinigen oder Trennen von Flüssigkeiten und Gasen, zum Binden chemischer Substanzen, zum Trocknen von Gasen oder Flüssigkeiten sowie als Träger von Arzneistoffen verwendet.Due to the high absorbency, the large surface area and chemical stability Silicon dioxide as a catalyst carrier, for cleaning or separating liquids and gases, for Binding chemical substances, for drying Gases or liquids and as a carrier of Drugs used.

Eine magnetische Beeinflussung im Sinne eines Ein- oder Austrages, Steuerung, Positionierung oder separieren von polymerem Siliciumdioxid würde die Anwendung und Handhabung verfahrenstechnischer, chemischer, analytischer oder pharmazeutischer Vorgänge verbessern oder erst ermöglichen.A magnetic influence in the sense of a Entry or exit, control, positioning  or would separate polymeric silica the application and handling of process engineering, chemical, analytical or pharmaceutical Improve processes or enable them first.

Erfindungsgemäß wird deshalb vorgeschlagen, in die Matrix polymerer Siliciumdioxidverbindungen magnetische Materialen einzubinden.According to the invention it is therefore proposed in the matrix of polymeric silicon dioxide compounds to incorporate magnetic materials.

Fällungskieselsäuren und Kieselgele, denen hinsicht­ lich des Produktionsumfanges die größte Bedeutung zukommt, werden aus wäßrigen Alkalisilikatlösungen durch Fällung und Kondensation mit Mineralsäuren hergestellt.Precipitated silicas and silica gels, which respects most important in terms of production volume comes from aqueous alkali silicate solutions by precipitation and condensation with mineral acids produced.

Erfindungsgemäß wird vorgeschlagen, in Alkalisilikat­ lösungen wie z. B. Natrium-, Kalium- oder Aluminium­ silikatlösungen magnetische Materialen wie Fe, αFe2O3, γFe2O3 oder Fe3O4 zu dispergieren oder als kolloidale Lösungen hinzuzugeben und die Fällung sowie die Kondensation mit Mineralsäuren oder Kohlendioxid vorzunehmen.According to the invention, it is proposed to use solutions such as e.g. B. sodium, potassium or aluminum silicate solutions to disperse magnetic materials such as Fe, α Fe 2 O 3 , γ Fe 2 O 3 or Fe 3 O 4 or to add them as colloidal solutions and to carry out the precipitation and condensation with mineral acids or carbon dioxide.

Auch können die magnetischen Eisenoxide in Mineral­ säuren gelöst und diese dann zur Fällung und Konden­ sation verwendet werden.Also, the magnetic iron oxides in mineral acids dissolved and then for precipitation and condensation sation can be used.

Die mit diesen Methoden in die Alkalisilikatlösungen eingebrachten magnetischen Materialen werden nach Beendigung der Kondensation fest in die Matrix des entstandenen polymeren Siliciumdioxids eingebun­ den.Those with these methods in the alkali silicate solutions Magnetic materials that have been brought in are Termination of condensation firmly in the matrix of the resulting polymeric silicon dioxide the.

Überschüssige, also nicht in der Matrix des Silicium­ dioxids befindlichen magnetische Partikel können durch filtrieren oder zentrifugieren vom Produkt abgetrennt werden.Excess, not in the silicon matrix Magnetic particles located in dioxides can by filtering or centrifuging the product be separated.

Magnetische Kieselsole werden aus in Alkalisilikat­ lösungen dispergierten magnetischen Partikeln oder durch Zugabe kolloidaler magnetischer Lösungen und anschließender Kondensation durch Behandeln mit Kationentauscher hergestellt. Auch durch die Zugabe von Mineralsäuren zu derar­ tigen, mit magnetischen Materialen versetzten Alkalisilikatlösungen und deren Wasserentzug durch wasserlösliche organische Lösungsmittel wie z. B. Äthanol oder Atzeton könne ebenfalls magnetische Kieselsole hergestellt werden. Durch filtrieren, dialysieren oder zentrifugieren werden die magnetischen Kieselsole von überschüssigen magnetischen Materialen, Lösungsmitteln und Salzen gereinigt.Magnetic silica sols are made from alkali silicate solutions dispersed magnetic particles  or by adding colloidal magnetic solutions and subsequent condensation by treatment made with cation exchanger. Also by adding mineral acids to derar with magnetic materials Alkali silicate solutions and their water removal through water-soluble organic solvents such as B. Ethanol or acetone can also be magnetic Silica sols are produced. By filtering, dialyzing or centrifuging the magnetic silica sols from excess magnetic materials, solvents and salts cleaned.

Pyrogene magnetische Kieselsäure wird durch die gemeinsame Verdüsung von Siliciumtrachlorid mit magnetischen Suspensionen oder kolloidalen magne­ tischen Lösungen in einer Wasserstoffflamme herge­ stellt.Magnetic fumed silica is produced by the common atomization of silicon trachloride with magnetic suspensions or colloidal magne table solutions in a hydrogen flame poses.

Die dem polymeren Siliciumdioxid spezifische Ober­ fläche von 30-800 m2/g und die darauf befindlichen Silanol-(-SiOH) und Siloxan-(Si-O-Si) -Gruppierungen, die die Chemisorption über Wasserstoffbrückenbindung ermöglichen, werden durch die Matrixeinbindung magnetischer Substanzen nicht beeinträchtigt.The surface of 30-800 m 2 / g specific to the polymeric silicon dioxide and the silanol (- SiOH) and siloxane (Si-O-Si) groupings on it, which enable chemisorption via hydrogen bonding, become more magnetic due to the matrix integration Substances not affected.

Da vornehmlich über die Wasserstoffbrückenbindung zwischenmolekulare Verbindungen und Assoziierungen mit Molekülen der Gruppen -OH, - COOH, =NH, und -NH3 auftreten, können durch geeignete Maßnahmen wie des vollständigen oder teilweisen Ersatzes durch Alkylsilylreste, so z. B. mit Chlorsilane, andere Bindungsaffinitäten erzielt sowie der hydro­ phile oder hydrophobe Charakter variiert werden. Since intermolecular compounds and associations with molecules of the groups -OH, - COOH, = NH, and -NH 3 occur primarily via the hydrogen bond, suitable measures such as the complete or partial replacement by alkylsilyl radicals, such as e.g. B. achieved with chlorosilanes, other binding affinities and the hydro phile or hydrophobic character can be varied.

Das erfindungsgemäße magnetische polymere Silicium­ dioxid in Form von Kieselgel, Kieselsol und pyrogener oder Fällungskieselsäure ermöglicht neue oder verbesserte Anwendungen.The magnetic polymeric silicon according to the invention dioxide in the form of silica gel, silica sol and pyrogenic or precipitated silica enables new or improved applications.

So können die zur Reinigung oder Trennung von Flüssigkeiten oder Gasen, wie z. B. die Entfernung von Aromaten aus Paraffinen oder der Öldampfabsorp­ tion, beladenen magnetischen Siliciumdioxidverbin­ dungen mit Hilfe externer Magnetfelder oder Magnet­ separatoren vorteilhaft ausgetragen werden.So you can for cleaning or separation of Liquids or gases, such as B. distance of aromatics from paraffins or the oil vapor absorber tion, loaded magnetic silica compound with the help of external magnetic fields or magnets separators are advantageously carried out.

Die Gewinnung und der Austrag von Produkten sowie die Magnetisierung von Bakterien oder Pilzen im Bereich der Biotechnologie, der biologischen Abwasser und Luftreinigung, können durch magnetisches Silici­ umdioxid ermöglicht oder verbessert werden.The extraction and discharge of products as well the magnetization of bacteria or fungi in the Field of biotechnology, biological wastewater and air cleaning, can be done by magnetic silicon dioxide made possible or improved.

Durch magnetische Kräfte, die auf die als Katalysa­ torträger verwendeten magnetischen Siliciumdioxid­ partikel einwirken, kann ein ungewollter Austrag verhindert, aber auch die Verteilung oder eine lokale Anreicherung der Katalysatoren, wie sie z. B. für Oxo-Prozesse oder Hydrierungen Anwendung finden, erzielt werden.By magnetic forces acting on the catalytic converter Magnetic silica used for the door support particles can cause an unwanted discharge prevented, but also the distribution or one local enrichment of the catalysts as they e.g. B. for oxo processes or hydrogenations application find, be achieved.

Die Schüttdichte der magnetischen Siliciumdioxidpar­ tikel in Abhängigkeit von Strömungs- oder Druckver­ hältnissen sowie Gas- oder Flüssigkeitszusammen­ setzungen, kann sowohl für die beschriebenen Anwen­ dungen als auch für die Trocknung von Gasen und Flüssigkeiten durch externe Magnetfelder den jewei­ ligen Betriebsbedingungen angepaßt werden.The bulk density of magnetic silica par particles depending on flow or pressure ver relationships as well as gas or liquid together settlements, can be used for the described applications as well as for drying gases and Liquids from external magnetic fields current operating conditions.

Die Aufnahme von magnetischem Siliciumdioxid, das zur Bindung von chemischen Kontaminationen wie Giften, Säuren, Basen und Mineralölen ausgebracht wird, kann vorteilhaft mit magnetischen Separatoren erfolgen. The absorption of magnetic silicon dioxide, to bind chemical contaminants such as poisons, acids, bases and mineral oils can be advantageous with magnetic separators respectively.  

Erfindungsgemäß können auf der Oberfläche magne­ tischer Siliciumdioxidpartikel pharmakologisch, biologisch oder biochemisch wirksame Substanzen wie z. B. Chemotherapeutika, Enzyme, Proteine, Hormone oder Antikörper gebunden, durch orale Aufnahme oder Injektion dem Organismus zugeführt werden und mit Hilfe magnetischer Hochgradientfelder am gewünschten Zielort angereichert werden. Syste­ misch bedingte Nebenwirkungen können so minimiert werden bei gleichzeitigem Erreichen hoher lokaler Wirkstoffkonzentration.According to the invention, magne on the surface table silica particles pharmacologically, biologically or biochemically active substances such as B. chemotherapeutic agents, enzymes, proteins, Hormones or antibodies bound by oral Intake or injection fed to the organism and with the help of magnetic high gradient fields be enriched at the desired destination. System Mixed side effects can be minimized become more local while reaching high Drug concentration.

Die Absorption und Bindung bestimmter Molekülgruppen, das hydrophobe oder hydrophile Verhalten sowie die Desorption der Wirkstoffe kann durch geeignete Maßnahmen wie den Ersatz freier Silanolgruppen auf der Oberfläche des magnetischen Siliciumdioxids variiert werden.The absorption and binding of certain groups of molecules, the hydrophobic or hydrophilic behavior as well the desorption of the active ingredients can be carried out by suitable Measures such as the replacement of free silanol groups on the surface of the magnetic silica can be varied.

Die Kopplung radioaktiver Isotope auf der Oberfläche magnetischer Siliciumdioxidpartikel kann durch lokale Anreicherung für diagnostische oder thera­ peutische Anwendungen wie der lokalen Strahlenthera­ pie, der Neutroneneinfangtherapie oder zur Erstellung von Szintigrammen genutzt werden.The coupling of radioactive isotopes on the surface magnetic silicon dioxide particles can by local enrichment for diagnostic or thera therapeutic applications such as the local radiation therapy pie, neutron capture therapy or to create can be used by scintograms.

Erfindungsgemäß können jod- oder bariumhaltige Röntgenkontrastmittel auf der Oberfläche magnetischer Siliciumdioxidpartikel gebunden und durch Anreiche­ rung in abzubildenen Arealen hohe Kontrastmittelkon­ zentration bei gleichzeitiger Entlastung des übrigen Organismus erreicht werden.According to the invention can contain iodine or barium X-ray contrast media on the surface of magnetic Silicon dioxide particles bound and by enrichment high contrast medium concentration in the areas to be imaged concentration while relieving the rest of the burden Organism can be achieved.

Da magnetisches Siliciumdioxid eine höhere Dichte als biologisches Gewebe aufweist, kann dieses hinsichtlich seiner lokalen Anreicherungsmöglichkeit für die Ultraschalldiagnostik Anwendung finden.Because magnetic silica has a higher density has as biological tissue, this can regarding its local enrichment possibility find application for ultrasound diagnostics.

Erfindungsgemäß können magnetische Siliciumdioxid­ partikel zur Erhöhung bei bildgebenden NMR-Diagnos­ tikverfahren angewendet werden.According to the invention, magnetic silicon dioxide  particles to increase in imaging NMR diagnosis tic procedures are applied.

Die Kopplung der Partikel mit gewebsspezifischen Bindungssubstanzen wie z. B. Antikörpern, Antigenen oder Proteinen und deren Affinität zu z. B. malignen Zellen ermöglicht über NMR- oder Ultraschalldiagnos­ tikverfahren das Auffinden von erkrankten Arealen wie z. B. Tumoren oder deren Metastasen.The coupling of the particles with tissue-specific Binding substances such as B. antibodies, antigens or proteins and their affinity for e.g. B. malign Cells enabled via NMR or ultrasound diagnostics technique to find diseased areas such as B. tumors or their metastases.

Durch gemeinsames Einbinden von jod- oder bariumhal­ tigen Verbindungen und magnetischen Substanzen in die Matrix von Siliciumdioxidpartikeln und deren Oberflächenbeschichtung mit gewebsspezifischen Bindungssubstanzen wird die gleiche Anwendung durch röntgendiagnostische Methoden ermöglicht. Erfindungsgemäß können magnetische Siliciumdioxid­ partikel in -vitro bestimmte Zellsorten, biologische Inhaltsstoffe oder DNA-Sequenzen für therapeutische oder diagnostische Zwecke isolieren, indem auf der Oberfläche biologische oder biochemisch aktive Substanzen aufgebracht und durch externe Magnetfelder abgeschieden werden.By integrating iodine or barium hal together compounds and magnetic substances into the matrix of silicon dioxide particles and their surface coating with tissue-specific Binding substances will have the same application made possible by X-ray diagnostic methods. According to the invention, magnetic silicon dioxide particles in-vitro specific cell types, biological Ingredients or DNA sequences for therapeutic or isolate diagnostic purposes by the surface is biologically or biochemically active Substances applied and by external magnetic fields be deposited.

Magnetische Siliciumdioxidpartikel können zur Bindung toxischer Stoffe, Bakterien oder Viren im Körper Anwendung finden. Die auch mit Komplexbil­ dnern wie z. B. Polykarbonsäuren und biologischen oder biochemischen Bindungssubstanzen wie z. B. Antikörper, Antigene, Hormone oder Proteine zu beschichtenden magnetischen Siliciumdioxidpartikel können über Gefäßkanulierungen außerhalb des Körpers durch Magnetfilter abgeschieden werden.Magnetic silicon dioxide particles can Binding of toxic substances, bacteria or viruses find application in the body. The one with complex bil thinners such as B. polycarboxylic acids and biological or biochemical binding substances such as. B. Antibodies, antigens, hormones or proteins too coating magnetic silica particles can via vascular cannulations outside the body be separated by magnetic filters.

Claims (17)

1. Magnetisches polymeres Siliciumdioxid in Form von Kieselgelen, Kieselsolen und gefälltem oder pyrogenen Siliciumdioxid gekennzeichnet durch die Einbindung magnetischer Materialen wie Fe, αFe2O3, γFe2O3, FeO4 in die Matrix der Siliciumdioxidverbindungen.1. Magnetic polymeric silicon dioxide in the form of silica gels, silica sols and precipitated or pyrogenic silicon dioxide characterized by the inclusion of magnetic materials such as Fe, α Fe 2 O 3 , γ Fe 2 O 3 , FeO 4 in the matrix of the silicon dioxide compounds. 2. Verfahren zur Herstellung magnetischer polymerer Siliciumdioxidverbindungen nach Anspruch 1 dadurch gekennzeichnet, das die magnetischen Materialen in Alkalisilikatlösungen wie Kalium-, Natrium- oder Aluminiumsilikatlösungen dispergiert oder als kolloidale Lösung hinzugegeben werden und mit Mineralsäuren oder Kohlendioxid gefällt und kondensiert werden.2. Process for producing magnetic polymer Silicon dioxide compounds according to claim 1 thereby featured the magnetic materials in alkali silicate solutions such as potassium, sodium or dispersed aluminum silicate solutions or be added as a colloidal solution and precipitated with mineral acids or carbon dioxide and be condensed. 3. Verfahren zur Herstellung magnetischer polymerer Siliciumdioxidverbindungen nach Abspruch 1 dadurch gekennzeichnet, daß magnetische Eisenoxide in Mineralsäuren gelöst und diese zur Fällung und Kondensation der Alkaisilikatlösungen verwendet werden.3. Process for producing magnetic polymer Silicon dioxide compounds according to claim 1 thereby characterized in that magnetic iron oxides in Mineral acids dissolved and for precipitation and Condensation of the alkali silicate solutions used become. 4. Verfahren zur Herstellung magnetischer polymerer Siliciumdioxidverbindungen nach Anspruch 1 dadurch gekennzeichnet, daß magnetische Kieselsole aus in Alkalisilikatlösungen dispergierten magnetischen Partikeln oder durch Zugabe kolloidaler magnetischer Lösungen und anschließender Fällung und Kondensation durch Kationentauscher, durch Zugabe von Mineral­ säuren oder durch Wasserentzug mit wasserlöslichen organischen Lösungsmitteln hergestellt werden. 4. Process for producing magnetic polymer Silicon dioxide compounds according to claim 1 thereby characterized in that magnetic silica sols Magnetic dispersed in alkali silicate solutions Particles or by adding colloidal magnetic Solutions and subsequent precipitation and condensation by cation exchangers, by adding mineral acids or by dehydration with water-soluble organic solvents.   5. Verfahren zur Herstellung magnetischer pyrogener Siliciumdioxidverbindungen nach Anspruch 1 dadurch gekennzeichnet, daß Siliciumtetrachlorid gemeinsam mit magnetischen Suspensionen oder kolloidalen magnetischen Lösungen in einer Wasserstoffflamme verdüst werden.5. Process for producing magnetic pyrogenic Silicon dioxide compounds according to claim 1 thereby characterized in that silicon tetrachloride together with magnetic suspensions or colloidal magnetic solutions in a hydrogen flame be atomized. 6. Magnetische polymere Siliciumdioxidpartikel nach Anspruch 1-5, dadurch gekennzeichnet, daß die spezifischen Oberflächen von 30-800 m2/g sowie die darauf befindlichen Silanol- und Siloxan- Gruppierungen, die für die Chemisorption über Wasserstoffbrückenbindung verantwortlich sind, durch den Einbau magnetischer Materialen nicht beeinträchtigt werden.6. Magnetic polymeric silicon dioxide particles according to claims 1-5, characterized in that the specific surfaces of 30-800 m 2 / g and the silanol and siloxane groups thereon, which are responsible for chemisorption via hydrogen bonding, by the incorporation of magnetic Materials are not affected. 7. Magnetische polymere Siliciumdioxidverbindungen nach Anspruch 1-5, dadurch gekennzeichnet, daß durch vollständigen oder teilweisen Ersatz durch Alkylsilylreste, so z. B. mit Chlorsilane, ein hydrophobes Verhalten, andere Bindungsaffinitäten sowie die Desorption von auf der Oberfläche des Siliciumdioxids gebundenen Substanzen verändert werden kann.7. Magnetic polymeric silicon dioxide compounds according to claims 1-5, characterized in that by full or partial replacement by Alkylsilyl radicals, e.g. B. with chlorosilanes hydrophobic behavior, other binding affinities as well as the desorption of on the surface of the Silicon-bound substances changed can be. 8. Magnetische Siliciumdioxidverbindungen nach Anspruch 1-7, dadurch gekennzeichnet, daß diese zur Reinigung, Trennung, Verteilung, Anreicherung oder für den Ein- und Austrag für Stofftrenn- und Gewinnungsverfahren, Trocknungsprozessen, als Katalysatorträger oder im Bereich der Biotech­ nologie Anwendung finden.8. Magnetic silica compounds after Claims 1-7, characterized in that this for cleaning, separation, distribution, enrichment or for the entry and exit for material separation and recovery processes, drying processes, as a catalyst carrier or in the field of biotech technology. 9. Magnetisches polymeres Siliciumdioxid nach Anspruch 1-7, dadurch gekennzeichnet, daß deren Schüttdichte durch Magnetfelder beeinflußt werden kann.9. Magnetic polymeric silica after Claims 1-7, characterized in that their  Bulk density can be influenced by magnetic fields can. 10. Magnetische Siliciumdioxidverbindungen nach Anspruch 1-7, dadurch gekennzeichnet, daß diese zur Bindung von Chemikalien ausgebracht und mit magnetischen Separatoren aufgenommen werden können.10. Magnetic silica compounds after Claims 1-7, characterized in that this applied to bind chemicals and with magnetic separators can be added. 11. Magnetische Siliciumdioxidverbindungen nach Anspruch 1-7, dadurch gekennzeichnet, daß deren Oberfläche mit pharmakologisch, biologisch oder biochemisch wirksamen Substanzen beschichtet, oral oder durch Injektion dem Organismus zugeführt und mit magnetischen Hochgradientfeldern lokal angereichert werden können.11. Magnetic silicon dioxide compounds after Claims 1-7, characterized in that their Surface with pharmacological, biological or coated with biochemically active substances, supplied to the organism orally or by injection and with magnetic high gradient fields locally can be enriched. 12. Magnetische polymere Siliciumdioxidverbindungen nach Anspruch 1-7, dadurch gekennzeichnet, daß auf deren Oberfläche radioaktive Isotope aufgebracht und lokal angereichert werden können.12. Magnetic polymeric silicon dioxide compounds according to claims 1-7, characterized in that radioactive isotopes applied to their surface and can be enriched locally. 13. Magnetische Siliciumdioxidverbindungen nach Anspruch 1-7, dadurch gekennzeichnet, daß auf deren Oberfläche Röntgenkontrastmittel aufgebracht und durch Magnetfelder lokale Anreicherungen im Organismus erzielt werden können.13. Magnetic silica compounds after Claims 1-7, characterized in that on X-ray contrast media applied to their surface and local enrichment through magnetic fields can be achieved in the organism. 14. Verfahren zur Herstellung magnetischer Silici­ umverbindungen nach Anspruch 1-7, dadurch gekennzei­ chnet, daß in deren Matrix magnetische Materialen und Röntgenkontrastmittel eingebunden werden.14. Process for the production of magnetic silicon re-connections according to claims 1-7, characterized chnet that in their matrix magnetic materials and X-ray contrast media can be integrated. 15. Magnetische Siliciumdioxidverbindungen nach Anspruch 1-7, dadurch gekennzeichnet, daß diese zur Kontrasterhöhung bei bildgebenden Ultraschall und NMR-Diagnostikverfahren Anwendung finden. 15. Magnetic silicon dioxide compounds after Claims 1-7, characterized in that this for increasing contrast in imaging ultrasound and NMR diagnostic methods find application.   16. Magnetische Siliciumdioxidverbindungen nach Anspruch 1-7, dadurch gekennzeichnet, daß diese auf der Oberfläche mit biologisch oder biochemisch aktiven Substanzen beschichtet und zur Isolierung von Zellen, biologischen Inhaltsstoffen oder DNA-Sequenzen mit Magnetfeldern verwendet werden können.16. Magnetic silicon dioxide compounds after Claims 1-7, characterized in that this on the surface with biological or biochemical active substances coated and for insulation of cells, biological ingredients or DNA sequences with magnetic fields can be used can. 17. Magnetische Siliciumdioxidverbindungen nach Anspruch 1-7, dadurch gekennzeichnet, daß diese zum extra- oder intrakorporalen Austrag oder Bindung von biologischen Inhaltsstoffen, toxischen Substanzen, Bakterien oder Viren aus dem Organismus mit Hilfe von Magnetfeldern verwendet werden können.17. Magnetic silica compounds after Claims 1-7, characterized in that this for extra or intracorporeal discharge or Binding of biological ingredients, toxic Substances, bacteria or viruses from the organism can be used with the help of magnetic fields can.
DE4307262A 1993-03-02 1993-03-02 Magnetic polymeric silicon dioxide Withdrawn DE4307262A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE4307262A DE4307262A1 (en) 1993-03-02 1993-03-02 Magnetic polymeric silicon dioxide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4307262A DE4307262A1 (en) 1993-03-02 1993-03-02 Magnetic polymeric silicon dioxide

Publications (1)

Publication Number Publication Date
DE4307262A1 true DE4307262A1 (en) 1994-09-08

Family

ID=6482234

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4307262A Withdrawn DE4307262A1 (en) 1993-03-02 1993-03-02 Magnetic polymeric silicon dioxide

Country Status (1)

Country Link
DE (1) DE4307262A1 (en)

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041811A1 (en) * 1995-06-08 1996-12-27 Boehringer Mannheim Gmbh Magnetic pigment
EP0757106A2 (en) * 1995-07-07 1997-02-05 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
WO1998012717A1 (en) * 1996-09-20 1998-03-26 Merck Patent Gmbh Spherical magnetic particles
WO1998031461A1 (en) * 1997-01-21 1998-07-23 W.R. Grace & Co.-Conn. Silica adsorbent on magnetic substrate
EP0895546A1 (en) * 1997-01-21 1999-02-10 Promega Corporation Methods of isolating biological target materials using silica magnetic particles
EP0937497A2 (en) * 1997-12-25 1999-08-25 Tosoh Corporation Magnetic carrier, preparation thereof, and method of extraction of nucleic acid
WO2000029562A1 (en) * 1998-11-06 2000-05-25 Merck Patent Gmbh Method of isolating plasmid dna
US6077487A (en) * 1997-11-05 2000-06-20 Millipore Corporation Process and apparatus of removing metal carbonyls and moisture from a gas
WO2000038831A1 (en) * 1998-12-31 2000-07-06 Hexablock, Inc. Magneto absorbent
WO2000070040A1 (en) 1999-05-14 2000-11-23 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
US6270970B1 (en) 1999-05-14 2001-08-07 Promega Corporation Mixed-bed solid phase and its use in the isolation of nucleic acids
WO2001070365A1 (en) * 2000-03-20 2001-09-27 Institut Für Neue Materialien Gem. Gmbh Method for separating components from liquid and gaseous media with nanocomposites
US6310199B1 (en) 1999-05-14 2001-10-30 Promega Corporation pH dependent ion exchange matrix and method of use in the isolation of nucleic acids
EP1189699A1 (en) * 1999-04-13 2002-03-27 Unisearch Limited A photocatalyst
EP1284485A1 (en) * 2001-08-16 2003-02-19 Degussa AG Superparamagnetic oxidic particles,their preparation process and application
DE10224410A1 (en) * 2002-05-30 2003-12-18 Ufz Leipzighalle Gmbh Sorbent for removing impurities, e.g. arsenic, sulfides, heavy metals and hydrogen sulfide, from aqueous and gaseous phases comprises mineral particles with crust of ferric hydroxide on silicate core
US6787307B1 (en) 1999-05-14 2004-09-07 Promega Corporation Lysate clearance and nucleic acid isolation using silanized silica matrices
DE19912799B4 (en) * 1998-03-12 2004-12-30 AGOWA Gesellschaft für molekularbiologische Technologie mbH Superparamagnetic adsorption material and its use
EP1613251A2 (en) * 2003-03-20 2006-01-11 Apneon Inc. Devices, systems, and methods to fixate tissue within the regions of body, such as the pharyngeal conduit
EP1621618A1 (en) * 1999-05-14 2006-02-01 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
WO2006077020A2 (en) 2005-01-18 2006-07-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for the specific or unspecific separation of cells and/or viruses from aqueous media and use thereof
US7188627B2 (en) 2002-09-06 2007-03-13 Apneon, Inc. Magnetic force devices, systems, and methods for resisting tissue collapse within the pharyngeal conduit
EP1907585A2 (en) * 2005-07-01 2008-04-09 Promega Corporation Network of buoyant particles for biomolecule purification and use of buoyant particles or network of buoyant particles for biomolecule purification
US7371830B2 (en) 1995-06-08 2008-05-13 Roche Diagnostics Gmbh Method for separating biological material from a fluid using magnetic particles
US7441559B2 (en) 2002-09-06 2008-10-28 Koninklijke Philips Electronics N.V. Devices, systems, and methods to fixate tissue within the regions of body, such as the pharyngeal conduit
US7481224B2 (en) 2003-01-22 2009-01-27 Koninklijke Philips Electronics N.V. Magnetic force device, systems, and methods for resisting tissue collapse within the pharyngeal conduit
DE19854973B4 (en) * 1998-11-30 2010-02-04 Institut Für Neue Materialien Gem. Gmbh Process for the purification of nucleic acids
US7721740B2 (en) 2002-09-06 2010-05-25 Koninklijke Philips Electronics N.V. Devices, systems, and methods using magnetic force systems in or on tissue
US7922917B2 (en) 2000-03-24 2011-04-12 Qiagen Gmbh Porous ferro- or ferrimagnetic glass particles for isolating molecules
US8001971B2 (en) 2002-09-06 2011-08-23 Koninklijke Philips Electronics N.V. Devices, systems, and methods for stabilization or fixation of magnetic force devices used in or on a body
US8020560B2 (en) 2002-09-06 2011-09-20 Koninklijke Philips Electronics N.V. Devices, systems and methods using magnetic force systems affecting the tongue or hyoid muscles in the upper airway
US8030034B2 (en) 2005-12-09 2011-10-04 Promega Corporation Nucleic acid purification with a binding matrix
US8039613B2 (en) 2009-08-28 2011-10-18 Promega Corporation Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
US8047206B2 (en) 2002-09-06 2011-11-01 Koninklijke Philips Electronics N.V. Magnetic devices, systems, and methods placed in or on a tongue
WO2012007581A1 (en) * 2010-07-15 2012-01-19 Aj Innuscreen Gmbh Method of concentrating bacteria, viruses and cells and for the subsequent isolation of nucleic acid
US8129118B2 (en) 1995-06-08 2012-03-06 Roche Diagnostics Gmbh Magnetic glass particles, method for their preparation and uses thereof
US8222397B2 (en) 2009-08-28 2012-07-17 Promega Corporation Methods of optimal purification of nucleic acids and kit for use in performing such methods
WO2013117583A1 (en) 2012-02-07 2013-08-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Magnetically separable microparticles with a silicate shell, method for production thereof and use thereof
US8511315B2 (en) 2002-09-06 2013-08-20 Koninklijke Philips N.V. Devices, systems and methods using magnetic force systems in the upper airway
US8528564B2 (en) 2002-09-06 2013-09-10 Koninklijke Philips N.V. Devices, systems and methods using magnetic force systems affecting both the tongue and the soft palate/uvula in the upper airway
US8657172B2 (en) 2006-11-06 2014-02-25 Avery Dennison Corporation Device for dispensing plastic fasteners
US8807137B2 (en) 2002-09-06 2014-08-19 Koninklijke Philips N.V. Self-anchoring magnetic force implant devices, systems, and methods
US8844537B1 (en) 2010-10-13 2014-09-30 Michael T. Abramson System and method for alleviating sleep apnea
US9161856B2 (en) 2002-09-06 2015-10-20 Koninklijke Philips N.V. Stabilized magnetic force devices, systems and methods
CZ305599B6 (en) * 2014-08-01 2015-12-30 Univerzita Pardubice Separation process of biopolymeric molecules and carrier for use in such a process
DE19549875B4 (en) * 1995-06-08 2016-12-08 Roche Diagnostics Gmbh Use of magnetic particles for the isolation of nucleic acids
US9969943B2 (en) 2013-09-30 2018-05-15 Maersk Olie Og Gas A/S Use of magnetic nanoparticles for depletion of aromatic compounds in oil
US9975790B2 (en) 2013-09-30 2018-05-22 Maersk Olie Og Gas A/S Water treatment suited for oil production wells
US10138410B2 (en) 2013-09-30 2018-11-27 Total E&P Danmark A/S Method and system for the enhanced recovery of oil, using water that has been depleted in ions using magnetic particles
US10150908B2 (en) 2013-09-30 2018-12-11 Total E&P Danmark A/S Method and system for the recovery of oil, using water that has been treated using magnetic particles
US20220055040A1 (en) * 2015-01-27 2022-02-24 Circulomics Inc. Hierarchical silica lamella for magnetic nucleic acid extractions

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281714A1 (en) * 1995-06-08 2003-02-05 Roche Diagnostics GmbH Magnetic pigment
EP1577389A3 (en) * 1995-06-08 2005-11-23 Roche Diagnostics GmbH Magnetic pigment
EP1602724A1 (en) * 1995-06-08 2005-12-07 Roche Diagnostics GmbH Magnetic pigment
WO1996041811A1 (en) * 1995-06-08 1996-12-27 Boehringer Mannheim Gmbh Magnetic pigment
US6870047B2 (en) 1995-06-08 2005-03-22 Roche Diagnostics Gmbh Magnetic pigment
US8129118B2 (en) 1995-06-08 2012-03-06 Roche Diagnostics Gmbh Magnetic glass particles, method for their preparation and uses thereof
EP1577389B1 (en) † 1995-06-08 2007-07-25 Roche Diagnostics GmbH Magnetic pigment
US7371830B2 (en) 1995-06-08 2008-05-13 Roche Diagnostics Gmbh Method for separating biological material from a fluid using magnetic particles
EP1577389A2 (en) * 1995-06-08 2005-09-21 Roche Diagnostics GmbH Magnetic pigment
EP1577389B2 (en) † 1995-06-08 2017-08-16 Roche Diagnostics GmbH A method for carrying out an enzymatic reaction on nucleic acids
DE19549875B4 (en) * 1995-06-08 2016-12-08 Roche Diagnostics Gmbh Use of magnetic particles for the isolation of nucleic acids
US7119194B2 (en) 1995-07-07 2006-10-10 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
EP0757106A2 (en) * 1995-07-07 1997-02-05 Toyo Boseki Kabushiki Kaisha Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same
WO1998012717A1 (en) * 1996-09-20 1998-03-26 Merck Patent Gmbh Spherical magnetic particles
EP0895546A1 (en) * 1997-01-21 1999-02-10 Promega Corporation Methods of isolating biological target materials using silica magnetic particles
US6447911B1 (en) 1997-01-21 2002-09-10 W. R. Grace & Co.-Conn. Silica adsorbent on magnetic substrate
EP1367137A1 (en) * 1997-01-21 2003-12-03 Promega Corporation Methods of isolating biological target materials using silica magnetic particles
US6296937B2 (en) 1997-01-21 2001-10-02 W. R. Grace & Co.-Conn. Silica adsorbent on magnetic substrate
CZ297990B6 (en) * 1997-01-21 2007-05-16 W. R. Grace & Co.-Conn. Particulate adsorbent and process for its preparation
US6368800B1 (en) 1997-01-21 2002-04-09 Promega Corporation Kits for isolating biological target materials using silica magnetic particles
WO1998031461A1 (en) * 1997-01-21 1998-07-23 W.R. Grace & Co.-Conn. Silica adsorbent on magnetic substrate
US6673631B1 (en) 1997-01-21 2004-01-06 Promega Corporation Simultaneous isolation and quantitation of DNA
US6027945A (en) * 1997-01-21 2000-02-22 Promega Corporation Methods of isolating biological target materials using silica magnetic particles
EP0895546A4 (en) * 1997-01-21 2002-03-20 Promega Corp Methods of isolating biological target materials using silica magnetic particles
US6077487A (en) * 1997-11-05 2000-06-20 Millipore Corporation Process and apparatus of removing metal carbonyls and moisture from a gas
US6503762B1 (en) 1997-12-25 2003-01-07 Tosoh Corporation Magnetic carrier, preparation thereof, and method of extraction of nucleic acid
US6274387B1 (en) 1997-12-25 2001-08-14 Tosoh Corporation Magnetic carrier, preparation thereof, and method of extraction of nucleic acid
EP0937497A2 (en) * 1997-12-25 1999-08-25 Tosoh Corporation Magnetic carrier, preparation thereof, and method of extraction of nucleic acid
EP0937497A3 (en) * 1997-12-25 1999-10-20 Tosoh Corporation Magnetic carrier, preparation thereof, and method of extraction of nucleic acid
DE19912799B4 (en) * 1998-03-12 2004-12-30 AGOWA Gesellschaft für molekularbiologische Technologie mbH Superparamagnetic adsorption material and its use
WO2000029562A1 (en) * 1998-11-06 2000-05-25 Merck Patent Gmbh Method of isolating plasmid dna
US6548253B1 (en) 1998-11-06 2003-04-15 Merck Patent Gmbh Method of isolating plasmid DNA
DE19854973B4 (en) * 1998-11-30 2010-02-04 Institut Für Neue Materialien Gem. Gmbh Process for the purification of nucleic acids
WO2000038831A1 (en) * 1998-12-31 2000-07-06 Hexablock, Inc. Magneto absorbent
US6706097B2 (en) 1998-12-31 2004-03-16 Hexablock, Inc. Molecular separator apparatus
EP1189699A1 (en) * 1999-04-13 2002-03-27 Unisearch Limited A photocatalyst
EP1189699A4 (en) * 1999-04-13 2003-06-25 Unisearch Ltd A photocatalyst
US7078224B1 (en) 1999-05-14 2006-07-18 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
JP2002543835A (en) * 1999-05-14 2002-12-24 プロメガ コーポレイション Cell collection and lysate clarification using paramagnetic particles
AU778486B2 (en) * 1999-05-14 2004-12-09 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
US6806362B2 (en) 1999-05-14 2004-10-19 Promega Corporation pH dependent ion exchange matrix and method of use in the isolation of nucleic acids
US6787307B1 (en) 1999-05-14 2004-09-07 Promega Corporation Lysate clearance and nucleic acid isolation using silanized silica matrices
US6310199B1 (en) 1999-05-14 2001-10-30 Promega Corporation pH dependent ion exchange matrix and method of use in the isolation of nucleic acids
EP1621618A1 (en) * 1999-05-14 2006-02-01 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
US6376194B2 (en) 1999-05-14 2002-04-23 Promega Corporation Mixed-bed solid phase and its use in the isolation of nucleic acids
US6270970B1 (en) 1999-05-14 2001-08-07 Promega Corporation Mixed-bed solid phase and its use in the isolation of nucleic acids
WO2000070040A1 (en) 1999-05-14 2000-11-23 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
WO2001070365A1 (en) * 2000-03-20 2001-09-27 Institut Für Neue Materialien Gem. Gmbh Method for separating components from liquid and gaseous media with nanocomposites
US6830694B2 (en) 2000-03-20 2004-12-14 Institut Fuer Neue Materialien Gemeinnuetzige Gmbh Method for separating components from liquid and gaseous media with nanocomposites
US8202427B2 (en) 2000-03-24 2012-06-19 Qiagen Gmbh Porous ferro-or ferrimagnetic glass particles for isolating molecules
US7922917B2 (en) 2000-03-24 2011-04-12 Qiagen Gmbh Porous ferro- or ferrimagnetic glass particles for isolating molecules
EP1284485A1 (en) * 2001-08-16 2003-02-19 Degussa AG Superparamagnetic oxidic particles,their preparation process and application
US6746767B2 (en) 2001-08-16 2004-06-08 Degussa Ag Superparamagnetic oxidic particles, processes for their production and their use
DE10224410A1 (en) * 2002-05-30 2003-12-18 Ufz Leipzighalle Gmbh Sorbent for removing impurities, e.g. arsenic, sulfides, heavy metals and hydrogen sulfide, from aqueous and gaseous phases comprises mineral particles with crust of ferric hydroxide on silicate core
US8001971B2 (en) 2002-09-06 2011-08-23 Koninklijke Philips Electronics N.V. Devices, systems, and methods for stabilization or fixation of magnetic force devices used in or on a body
US8020560B2 (en) 2002-09-06 2011-09-20 Koninklijke Philips Electronics N.V. Devices, systems and methods using magnetic force systems affecting the tongue or hyoid muscles in the upper airway
US8511315B2 (en) 2002-09-06 2013-08-20 Koninklijke Philips N.V. Devices, systems and methods using magnetic force systems in the upper airway
US8807137B2 (en) 2002-09-06 2014-08-19 Koninklijke Philips N.V. Self-anchoring magnetic force implant devices, systems, and methods
US7721740B2 (en) 2002-09-06 2010-05-25 Koninklijke Philips Electronics N.V. Devices, systems, and methods using magnetic force systems in or on tissue
US7441559B2 (en) 2002-09-06 2008-10-28 Koninklijke Philips Electronics N.V. Devices, systems, and methods to fixate tissue within the regions of body, such as the pharyngeal conduit
US7958895B2 (en) 2002-09-06 2011-06-14 Koninklijke Philips Electronics N.V. Magnetic force devices, systems, and methods for resisting tissue collapse within the pharyngeal conduit
US7958896B2 (en) 2002-09-06 2011-06-14 Koninklijke Philips Electronics N.V. Magnetic force devices, systems, and methods for resisting tissue collapse within the pharyngeal conduit
US8528564B2 (en) 2002-09-06 2013-09-10 Koninklijke Philips N.V. Devices, systems and methods using magnetic force systems affecting both the tongue and the soft palate/uvula in the upper airway
US7500484B2 (en) 2002-09-06 2009-03-10 Koninklijke Philips Electronics N.V. Magnetic force devices, systems, and methods for resisting tissue collapse within the pharyngeal conduit
US9161856B2 (en) 2002-09-06 2015-10-20 Koninklijke Philips N.V. Stabilized magnetic force devices, systems and methods
US7188627B2 (en) 2002-09-06 2007-03-13 Apneon, Inc. Magnetic force devices, systems, and methods for resisting tissue collapse within the pharyngeal conduit
US8047206B2 (en) 2002-09-06 2011-11-01 Koninklijke Philips Electronics N.V. Magnetic devices, systems, and methods placed in or on a tongue
US7481224B2 (en) 2003-01-22 2009-01-27 Koninklijke Philips Electronics N.V. Magnetic force device, systems, and methods for resisting tissue collapse within the pharyngeal conduit
EP1613251A4 (en) * 2003-03-20 2006-12-13 Apneon Inc Devices, systems, and methods to fixate tissue within the regions of body, such as the pharyngeal conduit
EP1613251A2 (en) * 2003-03-20 2006-01-11 Apneon Inc. Devices, systems, and methods to fixate tissue within the regions of body, such as the pharyngeal conduit
WO2006077020A2 (en) 2005-01-18 2006-07-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for the specific or unspecific separation of cells and/or viruses from aqueous media and use thereof
EP1907585A2 (en) * 2005-07-01 2008-04-09 Promega Corporation Network of buoyant particles for biomolecule purification and use of buoyant particles or network of buoyant particles for biomolecule purification
EP1907585A4 (en) * 2005-07-01 2010-04-07 Promega Corp Network of buoyant particles for biomolecule purification and use of buoyant particles or network of buoyant particles for biomolecule purification
US8030034B2 (en) 2005-12-09 2011-10-04 Promega Corporation Nucleic acid purification with a binding matrix
US8658360B2 (en) 2005-12-09 2014-02-25 Promega Corporation Nucleic acid purification with a binding matrix
US9802727B2 (en) 2006-11-06 2017-10-31 Avery Dennison Corporation Device for dispensing plastic fasteners
US8657172B2 (en) 2006-11-06 2014-02-25 Avery Dennison Corporation Device for dispensing plastic fasteners
US8039613B2 (en) 2009-08-28 2011-10-18 Promega Corporation Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
US8519119B2 (en) 2009-08-28 2013-08-27 Promega Corporation Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
US8222397B2 (en) 2009-08-28 2012-07-17 Promega Corporation Methods of optimal purification of nucleic acids and kit for use in performing such methods
WO2012007581A1 (en) * 2010-07-15 2012-01-19 Aj Innuscreen Gmbh Method of concentrating bacteria, viruses and cells and for the subsequent isolation of nucleic acid
US8844537B1 (en) 2010-10-13 2014-09-30 Michael T. Abramson System and method for alleviating sleep apnea
US9763767B2 (en) 2010-10-13 2017-09-19 Michael T. Abramson System and method for alleviating sleep apnea
WO2013117583A1 (en) 2012-02-07 2013-08-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Magnetically separable microparticles with a silicate shell, method for production thereof and use thereof
DE102012201774A1 (en) 2012-02-07 2013-08-22 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Magnetically separable microparticles with a silicate shell, process for their preparation and their use
US9969943B2 (en) 2013-09-30 2018-05-15 Maersk Olie Og Gas A/S Use of magnetic nanoparticles for depletion of aromatic compounds in oil
US9975790B2 (en) 2013-09-30 2018-05-22 Maersk Olie Og Gas A/S Water treatment suited for oil production wells
US10138410B2 (en) 2013-09-30 2018-11-27 Total E&P Danmark A/S Method and system for the enhanced recovery of oil, using water that has been depleted in ions using magnetic particles
US10150908B2 (en) 2013-09-30 2018-12-11 Total E&P Danmark A/S Method and system for the recovery of oil, using water that has been treated using magnetic particles
CZ305599B6 (en) * 2014-08-01 2015-12-30 Univerzita Pardubice Separation process of biopolymeric molecules and carrier for use in such a process
US20220055040A1 (en) * 2015-01-27 2022-02-24 Circulomics Inc. Hierarchical silica lamella for magnetic nucleic acid extractions

Similar Documents

Publication Publication Date Title
DE4307262A1 (en) Magnetic polymeric silicon dioxide
CN105854964B (en) Micro-fluidic chip, preparation method and applications based on SERS detections
US3505785A (en) Superficially porous supports for chromatography
RU2304463C2 (en) One-nanometer positive fiber adsorbent
CN102888394B (en) Method for extracting nucleic acid and nucleic acid extraction cylinder
DE60306135T2 (en) IMPROVED SEPARATION
Liu et al. Fabrication of chiral amino acid ionic liquid modified magnetic multifunctional nanospheres for centrifugal chiral chromatography separation of racemates
US20090308811A1 (en) Chromatography device
Shimizu Self‐assembled organic nanotubes: Toward attoliter chemistry
DE10045434B4 (en) Adsorbent with differently modified surface areas, process for its preparation and use thereof
KR20160097120A (en) Method for Preparing an Optionally Functionalised Glass Having Bimodal Porosity, and Said Glass
Amiri et al. Solid-phase extraction of non-steroidal anti-inflammatory drugs in human plasma and water samples using sol–gel-based metal-organic framework coating
EP1278582B1 (en) Method for separating components from liquid and gaseous media with nanocomposites
Razdan et al. PolyBall: A new adsorbent for the efficient removal of endotoxin from biopharmaceuticals
Gómez-Pastora et al. The reverse of controlled release: Controlled sequestration of species and biotoxins into nanoparticles (NPs)
Mollahosseini et al. An improvement of electrospun membrane reusability via titanium dioxide nanoparticles and silane compounds for the electromembrane extraction
CN205886912U (en) Liquid drop self -powered dynamic formula micro -fluidic chip based on SERS detects
CN111235103A (en) Flow recognition nano vesicle for cell capture and preparation method and application thereof
KR100647335B1 (en) Cell separation method using hydrophobic solid supports
JP2006296427A (en) Cell separation method using hydrophobic solid support
Martins et al. From Impure to Purified Silver Nanoparticles: Advances and Timeline in Separation Methods
CN108889285B (en) Limited-feeding chromatographic packing, preparation method thereof, stationary phase containing limited-feeding chromatographic packing and application of stationary phase
Zhang et al. Endotoxin removal using a synthetic adsorbent of crystalline calcium silicate hydrate
US7959861B2 (en) Integrated affinity microcolumns and affinity capillary electrophoresis
Nojavan et al. Application of magnetic nanomaterials in bioanalysis

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee
8170 Reinstatement of the former position
8139 Disposal/non-payment of the annual fee